Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

Objective: Aberrations in the PI3K/AKT/mTOR survival pathway in many cancers are the most common genomic abnormalities. The phytochemical and bioactive agent sulforaphane (SFN) has nutrigenomic potential in activating the expression of several cellular protective genes via the transcription factor n...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Mokhtari, Reza Bayat, Qorri, Bessi, Baluch, Narges, Sparaneo, Angelo, Fabrizio, Federico Pio, Muscarella, Lucia Anna, Tyker, Albina, Kumar, Sushil, Cheng, Hai-Ling Margaret, Szewczuk, Myron R., Das, Bikul, Yeger, Herman
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2021
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8310668/
https://ncbi.nlm.nih.gov/pubmed/34316328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.28011
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares